PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: William Looney
The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling
Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting. Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, Strategy, pricing Tagged China, Glivec, Global IP, india, Novartis, oncologics, Patent, Supreme Court, TRIPs 6 Comments
Is There a Global Policy Gap on Cancer?
Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement
Monday, February 4, is World Cancer Day. Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the [...]
Customer Engagement: Can Technology Help Find That Sweet Spot?
In the rush toward customer engagement, can technology find the sweet spot?
Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week, with two days of speakers and workshops focused on the interrelated themes of Transformation and Innovation. The central question: if the business of pharma is changing at warp [...]
Posted in Events, Patient Communication, Sales, Technology, healthcare Tagged Cegedim Relationship Management, e-detailing, patient access, Sales, Technology 2 Comments
Public Interest in Private Science: New Pathways to Measuring R&D Success
Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question: are industry R&D priorities in synch with the changing burden of disease?
Medicines Patent Pool: Industry's Toe Still in the Water